Key facts
- BiVACOR’s last known valuation is $109.0M.
- It has raised $60.4M across 1 recorded rounds; the latest was Early Stage VC ($9.0M) in Jul 2024.
- Notable investors include National Institutes of Health, Texas Medical Center, Cormorant Asset Management, OneVentures, Advance Queensland — 18 tracked in total.
- BiVACOR has filed 1 Form D with the SEC, most recently Aug 2024 ($9.0M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for BiVACOR
Funding rounds
1 roundsAbout BiVACOR
Developer of an artificial heart-pumping device designed to take over the complete function of a patient's failing heart. The company's compact device comprises a magnetically levitated rotor between opposing pump casings and leverages rotary blood pump technology to provide the required cardiac output, enabling patients to reduce the risk of blood-cell damage and clotting and survive with a substitute blood pumping system.
- Sector
- Healthcare
- HQ
- Huntington Beach, CA, United States
- Founded
- 2008
- Employees
- 47
- Website
- bivacor.com/
- Ownership
- Privately Held (backing)
BiVACOR doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BiVACOR shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BiVACOR in its N-PORT filings yet. We sweep new filings monthly.